Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Институт биоорганической химии им. акад. М.М.Шемякина и Ю.А.Овчинникова РАН
Список исп. литературыСкрыть список 1. Lacro JP et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002; 63 (10): 892–909. 2. Eaddy MA, Locklear G. and J. Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population. Clin Ther 2005; 27 (2): 263–72. 3. Law MR et al. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J Clin Psychiatry 2008; 69 (1): 47–53. 4. Weiden PJ et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004; 55 (8): 886–91. 5. Morken G, Widen JH, Grawe RW. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry 2008; 8: p. 32. 6. Lindenmayer JP et al. Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. J Clin Psychiatry 2009; 70 (7): 990–6. 7. Alia-Klein N et al. Insight into illness and adherence to psychotropic medications are separately associated with violence severity in a forensic sample. Aggress Behav 2007; 33 (1): 86–96. 8. Herings RM, Erkens JA. Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiol Drug Saf 2003; 12 (5): 423–4. 9. Ascher-Svanum H et al. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 2006; 67 (3): 453–60. 10. Schooler NR. Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry 2003; 64 (Suppl. 16): 14–7. 11. Taylor DM et al. Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients. J Clin Psychiatry 2004; 65 (8): 1076–83. 12. Marinis TD et al. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia. Pharmacopsychiatry 2007; 40 (6): 257–63. 13. Niaz OS, Haddad PM. Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. Acta Psychiatr Scand 2007; 116 (1): 36–46. 14. Olivares JM et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 2009; 24 (5): 287–96. 15. Peuskens J et al. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. Curr Med Res Opin 2010; 26 (3): 501–9. 16. Lambert T et al. Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium. Ann Gen Psychiatry 2011; 10: p. 10. 17. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000; 342 (25): 1878–86. 18. Любов Е.Б., Короткова Е.С. Многосторонняя оценка эффективности Pисполепта Kонста при лечении шизофрении (данные 9 мес наблюдения пациентов российской когорты исследования е-STAR). Соц. и клин. психиатрия. 2009: 19 (4): 61–4. 19. Zhao Z et al. Suicidal ideation, violent behavior, and self-injury in schizophrenia patients treated with long acting risperidone: 12-month results from e-STAR. Schizophrenia Research 2008; 102 (Suppl. 2): 1–3. 20. Olivares JM et al. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia: a 12- and 24-month follow-up from the e-STAR database in Spain. Appl Health Econ Health Policy 2008; 6 (1): 41–53. 21. Jacobs A et al. Patient and physician satisfaction with risperidone long-acting injection (RLAI). Schizophrenia Research 2008; 102 (Suppl. 2): 1–3.